|
Love this story...
http://www.zacks.com/stock/news/22951/Vi... However, with the FDA holding an advisory panel meeting on the subject on August 4, 2009, we are afraid that the end is near. We model a significant decline in Vancocin sales starting in the fourth quarter. This is a major concern for the top-line growth at ViroPharma. Sentiment : Strong Buy Rating :
 (No ratings) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.03